These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1175 related articles for article (PubMed ID: 15870416)

  • 1. Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents.
    Iakovou I; Schmidt T; Bonizzoni E; Ge L; Sangiorgi GM; Stankovic G; Airoldi F; Chieffo A; Montorfano M; Carlino M; Michev I; Corvaja N; Briguori C; Gerckens U; Grube E; Colombo A
    JAMA; 2005 May; 293(17):2126-30. PubMed ID: 15870416
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of platelet reactivity after clopidogrel administration on drug-eluting stent thrombosis.
    Buonamici P; Marcucci R; Migliorini A; Gensini GF; Santini A; Paniccia R; Moschi G; Gori AM; Abbate R; Antoniucci D
    J Am Coll Cardiol; 2007 Jun; 49(24):2312-7. PubMed ID: 17572245
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Early and late coronary stent thrombosis of sirolimus-eluting and paclitaxel-eluting stents in routine clinical practice: data from a large two-institutional cohort study.
    Daemen J; Wenaweser P; Tsuchida K; Abrecht L; Vaina S; Morger C; Kukreja N; Jüni P; Sianos G; Hellige G; van Domburg RT; Hess OM; Boersma E; Meier B; Windecker S; Serruys PW
    Lancet; 2007 Feb; 369(9562):667-78. PubMed ID: 17321312
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Correlates and long-term outcomes of angiographically proven stent thrombosis with sirolimus- and paclitaxel-eluting stents.
    Kuchulakanti PK; Chu WW; Torguson R; Ohlmann P; Rha SW; Clavijo LC; Kim SW; Bui A; Gevorkian N; Xue Z; Smith K; Fournadjieva J; Suddath WO; Satler LF; Pichard AD; Kent KM; Waksman R
    Circulation; 2006 Feb; 113(8):1108-13. PubMed ID: 16490815
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Analysis of the mechanisms of thrombosis after implantation of drug-eluting stents].
    Chen JL; Yang YJ; Qiao SB; Huang JH; Yao M; Qin XW; Xu B; Liu HB; Wu YJ; Gao RL
    Zhonghua Nei Ke Za Zhi; 2007 Mar; 46(3):197-9. PubMed ID: 17547799
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Improved late clinical safety with zotarolimus-eluting stents compared with paclitaxel-eluting stents in patients with de novo coronary lesions: 3-year follow-up from the ENDEAVOR IV (Randomized Comparison of Zotarolimus- and Paclitaxel-Eluting Stents in Patients With Coronary Artery Disease) trial.
    Leon MB; Nikolsky E; Cutlip DE; Mauri L; Liberman H; Wilson H; Patterson J; Moses J; Kandzari DE;
    JACC Cardiovasc Interv; 2010 Oct; 3(10):1043-50. PubMed ID: 20965463
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Incidence, predictors and outcome of drug-eluting stent thrombosis in real-world practice.
    Blich M; Zeidan-Shwiri T; Petcherski S; Osherov A; Hammerman H
    J Invasive Cardiol; 2010 Oct; 22(10):461-4. PubMed ID: 20944183
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical outcomes and stent thrombosis following off-label use of drug-eluting stents.
    Win HK; Caldera AE; Maresh K; Lopez J; Rihal CS; Parikh MA; Granada JF; Marulkar S; Nassif D; Cohen DJ; Kleiman NS;
    JAMA; 2007 May; 297(18):2001-9. PubMed ID: 17488965
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The unrestricted use of sirolimus- and paclitaxel-eluting stents results in better clinical outcomes during 6-year follow-up than bare-metal stents: an analysis of the RESEARCH (Rapamycin-Eluting Stent Evaluated At Rotterdam Cardiology Hospital) and T-SEARCH (Taxus-Stent Evaluated At Rotterdam Cardiology Hospital) registries.
    Simsek C; Magro M; Boersma E; Onuma Y; Nauta ST; Gaspersz MP; van der Giessen WJ; van Domburg RT; Serruys PW;
    JACC Cardiovasc Interv; 2010 Oct; 3(10):1051-8. PubMed ID: 20965464
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Risk factors for stent thrombosis after implantation of sirolimus-eluting stents in diabetic and nondiabetic patients: the EVASTENT Matched-Cohort Registry.
    Machecourt J; Danchin N; Lablanche JM; Fauvel JM; Bonnet JL; Marliere S; Foote A; Quesada JL; Eltchaninoff H; Vanzetto G;
    J Am Coll Cardiol; 2007 Aug; 50(6):501-8. PubMed ID: 17678732
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clopidogrel use and long-term clinical outcomes after drug-eluting stent implantation.
    Eisenstein EL; Anstrom KJ; Kong DF; Shaw LK; Tuttle RH; Mark DB; Kramer JM; Harrington RA; Matchar DB; Kandzari DE; Peterson ED; Schulman KA; Califf RM
    JAMA; 2007 Jan; 297(2):159-68. PubMed ID: 17148711
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Two-year outcomes after first- or second-generation drug-eluting or bare-metal stent implantation in all-comer patients undergoing percutaneous coronary intervention: a pre-specified analysis from the PRODIGY study (PROlonging Dual Antiplatelet Treatment After Grading stent-induced Intimal hyperplasia studY).
    Valgimigli M; Tebaldi M; Borghesi M; Vranckx P; Campo G; Tumscitz C; Cangiano E; Minarelli M; Scalone A; Cavazza C; Marchesini J; Parrinello G;
    JACC Cardiovasc Interv; 2014 Jan; 7(1):20-8. PubMed ID: 24332420
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sirolimus-eluting stent or paclitaxel-eluting stent vs balloon angioplasty for prevention of recurrences in patients with coronary in-stent restenosis: a randomized controlled trial.
    Kastrati A; Mehilli J; von Beckerath N; Dibra A; Hausleiter J; Pache J; Schühlen H; Schmitt C; Dirschinger J; Schömig A;
    JAMA; 2005 Jan; 293(2):165-71. PubMed ID: 15644543
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Randomized comparison of everolimus-eluting stents and sirolimus-eluting stents in patients with ST elevation myocardial infarction: RACES-MI trial.
    Di Lorenzo E; Sauro R; Varricchio A; Capasso M; Lanzillo T; Manganelli F; Carbone G; Lanni F; Pagliuca MR; Stanco G; Rosato G; Suryapranata H; De Luca G
    JACC Cardiovasc Interv; 2014 Aug; 7(8):849-56. PubMed ID: 25147029
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical and angiographic outcome after implantation of drug-eluting stents in bifurcation lesions with the crush stent technique: importance of final kissing balloon post-dilation.
    Ge L; Airoldi F; Iakovou I; Cosgrave J; Michev I; Sangiorgi GM; Montorfano M; Chieffo A; Carlino M; Corvaja N; Colombo A
    J Am Coll Cardiol; 2005 Aug; 46(4):613-20. PubMed ID: 16098424
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Stent thrombosis in randomized clinical trials of drug-eluting stents.
    Mauri L; Hsieh WH; Massaro JM; Ho KK; D'Agostino R; Cutlip DE
    N Engl J Med; 2007 Mar; 356(10):1020-9. PubMed ID: 17296821
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Outcomes and complications associated with off-label and untested use of drug-eluting stents.
    Beohar N; Davidson CJ; Kip KE; Goodreau L; Vlachos HA; Meyers SN; Benzuly KH; Flaherty JD; Ricciardi MJ; Bennett CL; Williams DO
    JAMA; 2007 May; 297(18):1992-2000. PubMed ID: 17488964
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Drug-eluting vs bare-metal stents in primary angioplasty: a pooled patient-level meta-analysis of randomized trials.
    De Luca G; Dirksen MT; Spaulding C; Kelbaek H; Schalij M; Thuesen L; van der Hoeven B; Vink MA; Kaiser C; Musto C; Chechi T; Spaziani G; Díaz de la Llera LS; Pasceri V; Di Lorenzo E; Violini R; Cortese G; Suryapranata H; Stone GW;
    Arch Intern Med; 2012 Apr; 172(8):611-21; discussion 621-2. PubMed ID: 22529227
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Randomized comparison of everolimus-eluting and paclitaxel-eluting stents: two-year clinical follow-up from the Clinical Evaluation of the Xience V Everolimus Eluting Coronary Stent System in the Treatment of Patients with de novo Native Coronary Artery Lesions (SPIRIT) III trial.
    Stone GW; Midei M; Newman W; Sanz M; Hermiller JB; Williams J; Farhat N; Caputo R; Xenopoulos N; Applegate R; Gordon P; White RM; Sudhir K; Cutlip DE; Petersen JL;
    Circulation; 2009 Feb; 119(5):680-6. PubMed ID: 19171853
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Meta-analysis of everolimus-eluting versus paclitaxel-eluting stents in coronary artery disease: final 3-year results of the SPIRIT clinical trials program (Clinical Evaluation of the Xience V Everolimus Eluting Coronary Stent System in the Treatment of Patients With De Novo Native Coronary Artery Lesions).
    Dangas GD; Serruys PW; Kereiakes DJ; Hermiller J; Rizvi A; Newman W; Sudhir K; Smith RS; Cao S; Theodoropoulos K; Cutlip DE; Lansky AJ; Stone GW
    JACC Cardiovasc Interv; 2013 Sep; 6(9):914-22. PubMed ID: 24050859
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 59.